Want to see GLUE full AI Analyst Report?
Monte Rosa Therapeutics (GLUE) Income Statement
Monte Rosa Therapeutics Income Statement
Last quarter (Q2 2026), Monte Rosa Therapeutics's total revenue was $8.97M, a decrease of 61.33% from the same quarter last year. In Q2, Monte Rosa Therapeutics's net income was $-43.40M. See Monte Rosa Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 123.67M | $ 75.62M | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 115.32M | $ 67.50M | $ -6.22M | $ 0.00 | $ 0.00 | |
| $ 169.52M | $ 148.61M | $ 137.09M | $ 112.38M | $ 72.88M | |
| Depreciation and Amortization | $ 8.36M | $ 8.12M | $ 6.22M | $ 3.75M | $ 2.13M |
| $ -31.37M | $ -62.01M | $ -128.79M | $ -100.99M | $ -71.83M | |
| $ -54.21M | $ -81.11M | $ -143.31M | $ -112.38M | $ -72.88M | |
| $ 14.48M | $ 10.98M | $ 8.30M | $ 3.88M | $ -1.08M | |
| $ -39.72M | $ -70.13M | $ -135.01M | $ -108.50M | $ -73.96M | |
| $ -38.63M | $ -72.70M | $ -135.35M | $ -108.50M | $ -73.96M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.59 | $ -0.98 | $ -2.63 | $ -2.30 | $ -1.59 |
| Diluted EPS | $ -0.59 | $ -0.98 | $ -2.63 | $ -2.30 | $ -1.59 |
| Weighted Average Shares Outstanding | 65.54M | 73.91M | 51.40M | 47.23M | 46.54M |
| Weighted Average Shares Outstanding (Diluted) | 65.54M | 73.91M | 51.40M | 47.23M | 46.54M |
Currency in USD